Core viewpoints

On the evening of October 27, the company released its report for the third quarter of 2023, in which Q3 achieved operating income of 1.84 billion yuan in a single quarter, down 6.36% from the same period last year. The slowdown in revenue growth is expected to be mainly due to the short-term pressure caused by the adjustment of the business structure of the company's commercial sector. The net profit was 163 million yuan, an increase of 4.20% over the same period last year. The net profit after deduction was 133 million yuan, an increase of 15.61% over the same period last year. The better profit growth was mainly due to the steady growth of the industrial sector with strong profitability, and the steady improvement in the operating quality of the superimposed company. On the whole, the performance of the main business is in line with our previous expectations. As the company continues to build the two core business platforms of chronic disease management and high-quality traditional Chinese medicine, it is expected to enable the company to develop healthily for a long time, and is optimistic about the continuous improvement of the company's management quality.

Event

The company releases the third quarter report of 2023

On the evening of October 27, the company released its report for the third quarter of 2023. The operating income, return net profit and net profit after deduction in the first three quarters were 5.611 billion yuan, 386 million yuan and 311 million yuan respectively, up-9.40%, 3.58% and 19.60% respectively over the same period last year. The performance of the main business is in line with our previous expectations.

Brief comment

The industrial sector achieved steady growth, and Q3 performance was in line with expectations.